Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$13.42
-0.2%		$11.49
$4.19
▼
$17.58
$808M1.391.90 million shs539,702 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%-3.28%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
0.00%+1.13%+15.49%+94.49%+158.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$13.42
-0.2%		$11.49
$4.19
▼
$17.58
$808M1.391.90 million shs539,702 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%-3.28%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
0.00%+1.13%+15.49%+94.49%+158.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.83
Moderate Buy$53.50298.66% Upside

Current Analyst Ratings Breakdown

Latest 4BB, SLN, OXB, and PRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$25.00 ➝ $32.00
7/17/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
6/17/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$75.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.66M91.01N/AN/A$12.65 per share1.38
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$560K1,442.89N/AN/A$0.64 per share20.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$109.74MN/AN/AN/AN/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$88.61M-$1.28N/AN/AN/A-8,943.86%-106.94%-47.99%11/5/2026 (Estimated)

Latest 4BB, SLN, OXB, and PRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.1387-$0.26-$0.1213-$0.27$1.13 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
6.59
6.59
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
7.42
7.42

Institutional Ownership

CompanyInstitutional Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.34 million23.05 millionNot Optionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
10060.21 million58.40 millionNot Optionable

Recent News About These Companies

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-5am-venture-management-llc-makes-new-investment-in-silence-therapeutics-plc-sponsored-adr-sln-2026-08-26/
Research Analysts Issue Forecasts for SLN Q3 Earnings
August 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971191
Silence Therapeutics: Making Some Recent Noise
August 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938417-silence-therapeutics-making-some-recent-noise
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/silence-therapeutics-nasdaqsln-sees-strong-trading-volume-should-you-buy-2026-08-18/
What is HC Wainwright's Estimate for SLN Q3 Earnings?
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-sln-q3-earnings-2026-08-18/
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/investors-buy-high-volume-of-silence-therapeutics-call-options-nasdaqsln-2026-08-17/
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
August 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260814817164/en/Silence-Therapeutics-Announces-Closing-of-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters%E2%80%99-Option-to-Purchase-Additional-ADSs/
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
August 14, 2026  |  cityam.comhttps://www.cityam.com/silence-therapeutics-announces-closing-of-upsized-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-adss/
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
August 13, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974273/wall-street-analysts-predict-a-140-06-upside-in-silence-therapeutics-sln-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2974273
Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SLN/pressreleases/3781939/analysts-are-bullish-on-top-healthcare-stocks-moonlake-immunotherapeutics-mltx-silence-therapeutics-sln/
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3801838/silence-therapeutics-sln-receives-a-buy-from-morgan-stanley/
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/silence-therapeutics-nasdaqsln-shares-down-69-whats-next-2026-08-12/
Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HIMS/pressreleases/3794002/analysts-conflicted-on-these-healthcare-names-silence-therapeutics-sln-hims-hers-health-hims-and-syndax-pharmaceuticals-sndx/
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
August 11, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260811003332/en/silence-therapeutics-announces-pricing-of-upsized-175-million-underwritten-public-offering/
Morgan Stanley maintains Overweight rating on Silence Therapeutics
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4630896-morgan-stanley-maintains-overweight-rating-on-silence-therapeutics
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/silence-therapeutics-nasdaqsln-sees-unusually-high-trading-volume-whats-next-2026-08-11/
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934509-silence-therapeutics-plc-sln-discusses-top-line-results-from-sanreco-phase-ii-trial-of
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/silence-therapeutics-divesiran-hits-phase-ii-goal-sets-up-phase-iii-pv-trial-2026-08-11/
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934427-silence-therapeutics-plc-sln-discusses-top-line-results-from-sanreco-phase-ii-trial-of
Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silence-therapeutics-apos-divesiran-treat-191537672.html
Silence Therapeutics stock surges as divesiran trial results fuel optimism
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4629936-silence-therapeutics-stock-surges-as-divesiran-trial-results-fuel-optimism

New MarketBeat Followers Over Time

Media Sentiment Over Time

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)
As of 08/28/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$13.42 -0.03 (-0.22%)
As of 08/28/2026 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas